Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 8 | Arthritis Research & Therapy

Figure 8

From: Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis

Figure 8

Biodistribution of free or liposomal DxM-P in adjuvant arthritis. Concentration of DxM in blood (a) (n = 6), synovial membrane (b) (n = 3), spleen (c) (n = 3), and liver (d) (n = 3) at 0.5, 2, 8, 24, and/or 72, 96, and 288 hours after the initial i. v. treatment with free or liposomal DxM-P during the time course of AA (for details see Figure 1). * P ≤ 0.05, ** P ≤ 0.01 vs. AA/DxM-P; all Mann Whitney U-test; administration of free or liposomal DxM-P at the time points 0 hours, 24 hours, and 48 hours.

Back to article page